InflaRx IFRX
NASDAQ IFRX
$1.54 +0.09 (+6.21%)
At close: Oct 20, 2026 · 4:00 PM EDT

InflaRx (IFRX) Revenue (2023 - 2026)

Updated

InflaRx (IFRX) recorded Revenue of $45,834 in Q2 2026, up 2.7% from $44,635 a year earlier.

Analysis

InflaRx (IFRX) Revenue (2023 - 2026) Analysis & Trends

On a TTM basis, InflaRx's Revenue came in at $78,831 as of Jun 30, 2026, down 63.9% year-over-year; for FY2025, it came in at $33,138, down 81.3% from FY2024.

  • Across earlier years, Revenue came in at $177,161 in FY2024 (+161.0%) and $67,880 in FY2023.
  • The Q2 2026 figure is the highest quarterly Revenue since Q3 2024.
  • On a year-over-year basis, Revenue rose in three of the last five quarters, with growth averaging 115.5%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 22.97 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 25.31 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 16.99 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 16.61 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 14.41 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 15.38 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 10.05 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn 7.80 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 15.03 Bn
10 InflaRx 105.98 Mn -227.64 Mn 2.74 Mn 45,834.25
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 45,834.25
Dec 31, 2025 -39,497.16
Sep 30, 2025 27,858.58
Jun 30, 2025 44,635.43
Mar 31, 2025 37,906.76
Dec 31, 2024 -452.02
Sep 30, 2024 135,980.44
Jun 30, 2024 6,845.77
Mar 31, 2024 39,149.22
Dec 31, 2023 2,459.60
Sep 30, 2023 66,189.57
Jun 30, 2023 -456.26
API Access

InflaRx Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=revenue&ticker=IFRX&period=max&api_key=YOUR_API_KEY